FDA decision to restrict ESAs may boost business for Cerus

09/15/2008 | East Bay (Calif.) Business Times

The FDA's decision to restrict the use of erythropoiesis-stimulating agents in cancer patients with anemia likely will boost the number of blood transfusions in the U.S., said Dr. Laurence Corash, chief medical officer of Cerus Corp. The change is expected to increase demand for the company's products, including the Intercept blood-safety system, which has yet to obtain FDA approval.

View Full Article in:

East Bay (Calif.) Business Times

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA